Loading...
Cyclacel Pharmaceuticals, Inc.
CYCC•NASDAQ
Healthcare
Biotechnology
$16.04
$-1.11(-6.47%)
Cyclacel Pharmaceuticals, Inc. (CYCC) Financial Performance & Income Statement Overview
Review Cyclacel Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-89.76%
↓ 89.76%
Operating Income Growth
52.84%
↑ 52.84%
Net Income Growth
50.29%
↑ 50.29%
Operating Cash Flow Growth
50.41%
↑ 50.41%
Operating Margin
60404.76%
↑ 60404.76%
Gross Margin
128.57%
↑ 128.57%
Net Profit Margin
39747.62%
↑ 39747.62%
ROE
-3641.00%
↓ 3641.003%
ROIC
-413.06%
↓ 413.06%
Cyclacel Pharmaceuticals, Inc. (CYCC) Income Statement & Financial Overview
Review Cyclacel Pharmaceuticals, Inc.'s (CYCC) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | -$35000.00 | $10000.00 | $4000.00 |
| Cost of Revenue | $0.00 | $4000.00 | $0.00 | $2000.00 |
| Gross Profit | $0.00 | -$39000.00 | $10000.00 | $2000.00 |
| Gross Profit Ratio | $0.00 | $1.11 | $1.00 | $0.50 |
| R&D Expenses | $822.00 | $879000.00 | $950000.00 | $2.02M |
| SG&A Expenses | $4214.00 | $948000.00 | $1.24M | $1.63M |
| Operating Expenses | $5036.00 | $1.83M | $2.19M | $3.65M |
| Total Costs & Expenses | $0.00 | $1.83M | $2.19M | $3.65M |
| Interest Income | $6.00 | $30000.00 | $8000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $28000.00 |
| Depreciation & Amortization | $0.00 | $1000.00 | $1000.00 | $2000.00 |
| EBITDA | $0.00 | -$1.85M | -$2.18M | -$3.64M |
| EBITDA Ratio | $0.00 | $53.00 | -$217.60 | -$910.50 |
| Operating Income | $0.00 | -$1.83M | -$2.18M | -$3.64M |
| Operating Income Ratio | $0.00 | $52.23 | -$217.70 | -$911.00 |
| Other Income/Expenses (Net) | $0.00 | -$30000.00 | $10000.00 | -$25000.00 |
| Income Before Tax | -$81.00 | -$1.86M | -$2.17M | -$3.67M |
| Income Before Tax Ratio | $53.09 | -$216.70 | -$917.25 | |
| Income Tax Expense | $0.00 | $1.19M | -$210000.00 | -$412000.00 |
| Net Income | -$81.00 | -$3.05M | -$1957.00 | -$3.26M |
| Net Income Ratio | $87.14 | -$0.20 | -$814.25 | |
| EPS | $0.00 | -$1.42 | -$0.001 | -$1.80 |
| Diluted EPS | $0.00 | -$1.42 | -$0.001 | -$1.80 |
| Weighted Avg Shares Outstanding | $5.36M | $2.15M | $2.15M | $1.81M |
| Weighted Avg Shares Outstanding (Diluted) | $5.36M | $2.15M | $2.15M | $1.81M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan